Skip to main content

SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel

B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

  • RegistryNCT04185038
  • PhasePhase 1
  • StatusRecruiting
  • ConditionCentral Nervous System Tumor
  • SponsorSeattle Children's Hospital
How Study of B7-H3-Specific CAR T Cell Locore… worksNCT041850381 min

What the film says

Read the transcript

Diffuse midline glioma grows in a child's brainstem, where no surgeon can cut. Radiation buys time; half of these children live under a year.

The idea: teach the child's own immune cells to find the tumor, and deliver them straight into the brain.

T cells from the child's blood are fitted with a receptor for B7-H3, a marker most of these tumors carry. Then, instead of a vein, they go through a small catheter into the fluid around the brain, dose after dose, over months.

In the first twenty-one children, repeated doses were tolerable, and three were alive more than three and a half years after diagnosis.

BrainChild-03, at Seattle Children's, now asks the same question in more tumors. Public record; not medical advice.

Sources behind this film

  • PaperIntracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial

    Vitanza NA. Nat Med, 2025

    Brainstem tumor, no surgery; half of children with DIPG live under a year; T cells fitted with a receptor for B7-H3, a marker most of these tumors carry; Catheter into the fluid around the brain, repeated doses over months; Twenty-one children treated; tolerable; three alive at 44, 45, 52 months from diagnosis

  • ClinicalTrials.gov record NCT04185038

    T cells fitted with a receptor for B7-H3, a marker most of these tumors carry; Catheter into the fluid around the brain, repeated doses over months; Twenty-one children treated; tolerable; three alive at 44, 45, 52 months from diagnosis; Now asks the same question in more of these tumors

The drug

What is being tested.

Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter

Patients with supratentorial tumors will be assigned to Arm A, and will receive their treatment into the tumor cavity. Patients with either infratentorial or metastatic/leptomeningeal tumors will be assigned to Arm B, and will have their treatment delivered into the ventricular system. The first 3 patients enrolled onto the study must be at least 15 years of age and assigned to Arm A or Arm B.

The study

How the trial runs.

This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cavity or ventricular system in children and young adults with diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and recurrent or refractory CNS tumors.

A child or young adult meeting all eligibility criteria, including having a CNS catheter placed into the tumor resection cavity or into their ventricular system, and meeting none of the exclusion criteria, will have their T cells collected. The T cells will then be bioengineered into a second-generation CAR T cell that targets B7H3-expressing tumor cells. Patients will be assigned to one of 3 treatment arms based on location or type of their tumor.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Age ≥ 1 and ≤ 26 years
  • Diagnosis of refractory or recurrent CNS disease for which there is no standard therapy, or diagnosis of DIPG or DMG at any time point following completion of standard therapy
  • Able to tolerate apheresis, or has apheresis product available for use in manufacturing
  • CNS reservoir catheter, such as an Ommaya or Rickham catheter
  • Life expectancy ≥ 8 weeks
  • Lansky or Karnofsky score ≥ 60

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.